abstract: AZFc deletions of the Y chromosome are the major known genetic cause of spermatogenetic failure. Meiotic studies have shown a prevalence of synaptonemal complex fragmentation and an excess of early-stage sperm cells, suggesting that the maturation block could involve apoptosis. We present a prospective and observational study of apoptotic markers in the sperm of four AZFc-deleted patients and two non-obstructive azoospermic controls without an AZFc deletion. Polycaspases assays and terminal deoxynucleotidyl transferase dUDP nick-end labelling (TUNEL) assays were combined to evaluate the incidence of apoptosis in pre-meiotic, meiotic and post-meiotic germs cells identified, respectively, using anti-melanoma-associated antigen A4 (MAGE-A4), anti-synaptonemal complex protein 3 (SCP3) and anti-sperm acrosome membrane-associated protein 1 (SPACA1) antibodies. We detected apoptosis at all stages of AZFc-deletion spermatogenesis. Using the caspase assay, the incidence of positive cells was found to be heterogeneous for pre-meiotic (from 4.8 to 84.5%) and meiotic stages (from 7.9 to 57.6%), while for post-meiotic cells, the mean incidence was 6% in AZFc-deleted patients compared with 26.5% in controls (P , 0.05). Using the TUNEL assay, the mean percentage with DNA fragmentation for meiotic cells was 54.0% in AZFc-deleted patients compared with 20.3% in controls (P , 0.05), while the percentage of TUNEL-positive post-meiotic cells ranged from 5.3 to 44.7%. Spermatocyte loss in AZFc-deleted patients occurs via the apoptotic pathway. In post-meiotic cells, the lower incidence of apoptosis in testis from three of the four AZFc-deleted patients, compared with controls, is consistent with AZFc deletions having little negative impact on sperm quality.
Introduction
The AZFc deletion of the Y chromosome constitutes the most frequently known genetic cause of spermatogenetic failure, and is associated with hypospermatogenesis. Testicular biopsies frequently reveal a mixture of tubules in different phenotypic states: full spermatogenesis, meiotic maturation arrest or Sertoli cell only within the same biopsy. The AZFc deletion interval is homogeneous in extent and includes three protein-coding gene families: BPY2, DAZ and CDY (Kuroda- Kawaguchi et al., 2001) . Nevertheless, the complete deletion of the DAZ gene family is generally compatible with sperm production and even, in rare instances, natural conception (Chang et al., 1999; Saut et al., 2000; Patrat et al., 2010) . The variable levels of spermatogenic impairment in cases of AZFc deletion suggest that phenotypic expression is susceptible to both genetic and environmental factors (Oates et al., 2002; Stouffs et al., 2005) .
Studies have been carried out in AZFc-deleted patients to understand spermatogenesis impairment at the meiotic level. Immunocytochemistry on meiotic prophase spermatocytes showed a prevalence of synaptonemal complex (SC) fragmentation, dotted SCs and short asynapsis (Geoffroy-Siraudin et al., 2007) . Moreover, an excess of early meiotic stages was observed, suggesting that SC fragmentation could be due to apoptosis in spermatocytes. Until now, apoptosis during spermatogenesis has not been studied in patients bearing an AZFc deletion.
Apoptosis is a well-known regulatory mechanism, acting throughout spermatogenesis to maintain a constant number of cells entering meiosis, to provide quality control during meiosis and to preserve homeostasis between the germ cells and the Sertoli cells (Dunkel et al., 1997; Kierszenbaum, 2001) . It has been shown that apoptotic activity is increased in cases of severely deficient spermatogenesis, testicular cancer or pairing difficulties linked to chromosome translocations (Brugnon et al., 2010) . In humans, the apoptotic mechanisms underlying normal and abnormal spermatogenesis are poorly understood. It is striking to note the small number of studies describing apoptosis at different stages of abnormal human spermatogenesis. Moreover, no relation has been established between the percentage of apoptotic germinal cells at the various stages of spermatogenesis and meiotic abnormalities.
The aim of our study was to evaluate the incidence of apoptotic germ cells at pre-meiotic, meiotic and post-meiotic stages, in four patients carrying an AZFc deletion. We studied the expression of activated caspases (El-Domyati et al., 2009; Feinstein-Rotkopf and Arama, 2009 ) in spermatogonia, spermatocytes and spermatids labelled, respectively, with anti-melanoma-associated antigen A4 (MAGE-A4), anti-synaptonemal complex protein 3 (SCP3) and anti-sperm acrosome membrane-associated protein 1 (SPACA1) antibodies. Using a terminal deoxynucleotidyl transferase dUDP nick-end labelling (TUNEL) assay, we also determined the percentage of meiotic and post-meiotic cells with DNA fragmentation (Tesarik et al., 1998; Oldereid et al., 2001; Trifonova and Moens, 2009) . We compared the apoptotic profiles obtained for the four AZFc-deleted men with those of two patients presenting hypospermatogenesis but no AZFc deletion. The involvement of apoptosis during spermatogenesis in AZFc-deleted patients is discussed.
Materials and Methods

Patients and controls
All patients and controls included in this study consulted at our reproduction centre in Marseilles for couple infertility. They presented a normal phenotype and a normal karyotype. They underwent a testicular biopsy in our reproduction centre to recover testicular spermatozoa for ICSI, and gave their informed consent for the Appel d'Offre de Recherche Clinique protocol called 'Germinal apoptosis in men and medically assisted procreation', number 2007-AO0634-49, approved by our institutional scientific and ethical committee.
The study included three azoospermic patients (APOP 19, APOP 25 and APOP 33) and one cryoptozoospermic patient (APOP 10), all deleted for the AZFc interval of the Y chromosome. Each patient had a classic AZFc deletion, defined by the loss of the markers sY148 and sY254.
We also studied two non-obstructive azoospermic patients (APOP 32 and APOP 34) with a normal karyotype and no AZF interval deletion detected by standard Y chromosome microdeletion screening. They were selected on the basis of the retrieval of numerous spermatozoa on the testicular biopsy, and were considered as 'controls'. The clinical profiles of AZFc patients and controls are detailed in Table I .
Testicular cells
All patients and controls underwent a testicular biopsy for testicular sperm extraction. A small fragment was taken for histological analysis. Testicular biopsies were treated in our reproduction laboratory in order to extract spermatozoa for ICSI. Briefly, the testicular fragments were teased apart in 4 ml of FertiCult IVF medium (JCD, La Mulatière, France) to obtain a fine cell suspension. Testicular cells were split into eight tubes, each of them containing 1 ml of 90% PureSperm (JCD) density gradient monolayer made with FertiCult. Following centrifugation for 30 min at 1300 rpm, the spermatozoa-depleted supernatant suspensions were removed, pooled and reserved for the research protocol. Each 90% (spermatozoa) fraction was recovered and resuspended with 1 ml of Ferticult medium. After centrifugation at 1500 rpm, the supernatants were discarded and the final pellets were pooled and resuspended in a final volume of 20 ml. If spermatozoa were present (APOP 25, 32 and 34), this volume was diluted in SpermFreeze (JCD) medium and aliquoted into straws for cryopreservation. If the final pellets were devoid of spermatozoa (APOP 10, 19 and 33), they were added to the cells reserved for research. One part of this cell suspension was used for the caspase assay, and all the remaining cells were stored as previously described (Metzler-Guillemain and Guichaoua, 2000) .
Detection of biochemical markers of apoptosis
Caspase assay
Testicular cells were treated immediately after spermatozoa isolation for ICSI. The detection of activated caspases was performed using the FLICA pan caspase assay (Abcys), according to the manufacturer's instructions. The cell-permeable and non-cytotoxic fluorescent caspase inhibitor (FLICA) recognizes specific amino acid sequences of activated caspases and binds covalently by fluoromethylketone. The fluorogenic substrate (FAM) becomes fluorescent upon cleavage by the caspases. Briefly, the 150-fold solution was prepared in dimethyl sulfoxide and stored at 2208C in aliquots before use. Each aliquot was then diluted in phosphatebuffered saline (PBS) to obtain the 30-fold work solution on the day of the testicular biopsy. For each patient, the testicular cell suspension was adjusted to obtain a concentration of 10 6 cells/ml. Testicular cells were exposed to 20 ml of the 30× work solution in 600 ml of PBS for 1 h at 378C under 5% CO 2 . The samples were then washed twice in 1× buffer and fixed in suspension for 5 min in the dark. Cells were then spread by cytocentrifugation as previously described (MetzlerGuillemain and Guichaoua, 2000) . Eight slides were prepared for each patient. Slides were fixed for 5 min in 2% paraformaldehyde in PBS, rinsed in PBS and mounted with 4 ′ ,6-diamidino-2-phenylindole (DAPI) 100 ng/ml in Vectashield. Slides were then stored at 48C before immunocytochemistry.
TUNEL assay
For the TUNEL assay, cells were thawed and spread by cytocentrifugation (Metzler-Guillemain and Guichaoua, 2000) . Cytospun cells were first submitted to immunocytochemistry with antibodies to identify spermatocytes or post-meiotic cells before being processed in the TUNEL assay. Freshly cytospun thawed testicular cells were fixed in 2% paraformaldehyde for 5 min before immunocytochemistry with either anti-SCP3 or anti-SPACA1 antibodies. After immunocytochemistry, slides were fixed in 2% paraformaldehyde for 1 h at room temperature. DNA fragmentation was then detected using the in situ cell death kit (Roche, France) as recommended by the manufacturer, with minor modifications. Cells were permeabilized with sodium citrate 0.1% for 2 min on slides, and then rinsed twice in PBS. For each patient and control, three or four slides were processed, in order to observe at least 100 germ cells at meiotic or post-meiotic stages. Slides were exposed to the TUNEL mix according to the manufacturer's instructions. One negative control was done for each patient as well as a control using the label solution without the enzyme solution. Cells were counterstained and mounted with 100 ng/ml DAPI in Vectashield mounting medium.
Immunocytochemistry
Immunocytochemistry was performed on spread germ cells following the caspase assay, and on thawed and cytospun testicular germ cells before the TUNEL assay. Slides were rinsed in PBS and permeabilized using 0.3 or 0.5% Triton X-100, 3% normal goat serum in PBS for 30 min. Slides were blocked with 7% normal goat serum in PBS for 1 h. They were then incubated with mouse monoclonal anti-MAGE-A4 antibody at a dilution of 1/100 in PBS (a kind gift from Pr Spagnoli), or rabbit polyclonal anti-SCP3 antibody at a dilution of 1/200 in PBS (Abcam ab85621), or rabbit polyclonal anti-SPACA1 antibody at a dilution of 1/100 in PBS (HPA026744 ATLAS antibody, Stockholm, Sweden). The slides were incubated overnight in a moist chamber at 378C. After washes in PBS under gentle agitation, detection was performed using goat anti-rabbit Cy3 (Rockland/TEBU 611-04-122), Alexa fluor 488 goat anti-rabbit (Invitrogen), anti-mouse Cy3 (Abcam ab6945) or anti-mouse FITC (Jackson laboratory, 515-095-062) secondary antibodies at dilutions recommended by manufacturers for 1 h at 378C. Slides were then rinsed in PBS and mounted in Vectashield for brief microscopic examination before the TUNEL assay, or with 100 ng/ml DAPI in Vectashield mounting medium for analysis of caspase-reacted slides.
Fluorescence microscopy
Germ cells were observed using an Axioplan 2 imaging Zeiss microscope equipped with a Photometrics Cool SNAPfx CCD camera. Images were captured and merged using the Smartcapture software. When possible, at least 200 nuclei were analysed for each labelling in all patients and controls.
Statistical analysis
The frequency of germ cells showing apoptotic markers were compared with the x 2 test.
Results
Patients and controls
The characteristics of AZFc-deleted patients and controls are summarized in Table I . For patients APOP 10, APOP 19 and APOP 33, no spermatozoa were found in the testicular cell suspension obtained after testicular biopsy laceration. For patient APOP 25, for whom immotile spermatozoa were found and frozen, no live spermatozoa were found after thawing. For the two controls, live spermatozoa were recovered from the testicular biopsy, which were frozen in order to perform ICSI. The thawing test was positive, indicating the presence of sufficient live spermatozoa for ICSI. Caspase activation in spermatogonia and meiotic and post-meiotic germ cells
We used a polycaspases reacting kit as a generic probe for the detection of most caspases, to maximize detection of caspase-mediated apoptosis.
We quantified the caspase activation in spermatogonia, meiotic and post-meiotic cells in three AZFc-deleted men and two azoospermic men with an intact Y chromosome (Fig. 1A, Table II ). We were unable to perform the caspase assay for patient APOP 10 because fresh cells were not available.
We identified human spermatogonia using an anti-MAGE-A4 antibody (Aubry et al., 2001) . In both controls, APOP 32 and APOP 34, 15% of MAGE-A4-positive cells were caspase-positive. For AZFc-deleted patients, the results were heterogeneous. For APOP 25, MAGE-A4-positive cells were scarce on the slides, and none were caspase-positive. For APOP 19 and APOP 33, the incidence of caspase-positive spermatogonia was strikingly contrasted at 84.5 and 4.8%, respectively.
Spermatocytes were identified using an anti-SCP3 antibody. SCP3 is a component of the axial/lateral element of the SC, and its labelling can be observed from the leptotene to the diplotene stage (Lammers et al., 1994) . The proportion of caspase-positive meiotic cells was similar for the two controls, with a mean of 17.6%. Among patients carrying an AZFc deletion, the overall percentage of caspase-positive meiotic cells was 12%, but it varies from 7.9% (APOP 19) to 57.6% (APOP 25). Compared with the controls, we noted a significant difference in the percentage of caspase-positive cells for patient APOP 25 (P , 0.001), but not for the other AZFc patients who had lower percentages than the controls. Most caspasepositive meiotic cells were determined to be at early pachytene stages on the basis that the XY body was not visible.
Spermatids were identified using anti-SPACA1 antibody that binds to the acrosome of round and elongating spermatids (Hao et al., 2002) . For the controls, the mean percentage of caspase-positive post-meiotic cells was 26.5%. Among AZFc-deleted patients, the frequency of the caspase-positive post-meiotic stages varied from 3.6 to 11.7%, with a mean percentage of 6%, which was significantly lower than in the controls (P , 0.05).
DNA fragmentation in meiotic and post-meiotic germ cells: TUNEL assays
We used the TUNEL assay to determine the incidence of meiotic and post-meiotic cells with fragmented DNA. TUNEL DNA fragmentation was observed in meiotic and post-meiotic cells in both groups of patients (Fig. 1B, Table III ). For the AZFc-deleted patients, the overall percentage of meiotic TUNEL-positive cells was 54.0%, which was significantly higher than in the two non-AZFc-deleted patients (mean 20.3%) (P , 0.05). Three of the four AZFc-deleted patients had approximately the same profile with a high percentage of TUNEL-positive meiotic cells (from 34 to 89%). However, the other AZFc-deleted patient, APOP 33 showed a distinct profile with only 10% of meiotic cells being TUNEL-positive.
For post-meiotic cells, the mean percentage of TUNEL-positive cells was 17.4% in the controls. In AZFc-deleted patients, the percentage of post-meiotic TUNEL-positive cells ranged from 5.3 to 44.8%, with a mean percentage of 21%.
Meiosis study
The overall incidence of leptotene, zygotene and pachytene nuclei identified using the anti-SCP3 antibody were, respectively, 6.3, 7.9 and 85.8% for AZFc-deleted patients, and 0.7, 3.3 and 95.9 for the two controls. AZFc-deleted patients had significantly more cells in early meiosis, at the leptotene (P , 0.01) and zygotene (P , 0.01) stages (Table IV) Significant difference between AZFc del. and controls for leptotene (P , 0.001) and zygotene (P , 0.001) stages. Totals for patients and controls are marked in bold.
Discussion
The present study reports the incidence of two different types of apoptotic indicator in the germ cells of six patients presenting nonobstructive azoospermia, four with an AZFc deletion and two with no Y chromosome deletions and considered as controls. We found that in the patients with an intact Y chromosome, there were similar frequencies of apoptosis at each stage of spermatogenesis, with detection by either activated caspases or TUNEL-fragmented DNA. This is in agreement with previous studies showing the involvement of caspases in the human spermatogenic apoptotic pathway (El-Domyati et al., 2009; Kilic et al., 2009; Almeida et al., 2011) . Using both approaches combined with specific antibodies to identify germ cells, the spermatogenic profiles show some differences between controls and AZFc-deleted patients. We observed that, in spermatocytes, TUNEL DNA fragmentation was significantly higher in AZFc-deleted patients than in the two patients with hypospermatogenesis and intact Y chromosome. A previous study found an accumulation of early meiotic stages in three AZFc-deleted patients, suggesting that the AZFc region may have a direct effect on early meiotic prophase, and that the hypospermatogenesis in AZFc cases could be the result of increased apoptosis among spermatocytes (Geoffroy-Siraudin et al., 2007) . The present study of four new patients and this previous study showed an elevated percentage of primary spermatocytes at the leptotene or zygotene stage in AZFc-deleted men, compared with either the hypospermatogenic control patients without an AZFc deletion, in this study, or previously characterized cases of obstructive azoospermia (GeoffroySiraudin et al., 2007) . The excess of DNA fragmentation that we found in spermatocytes could be the consequence of a checkpoint triggering apoptotic germ cell loss during meiosis. Thus, our results indicate that the loss of spermatocytes in AZFc-deleted patients may occur via apoptosis. It has also been argued that AZFc microdeletions may lead to an increasing loss of germ cells over time and a decline in spermatozoa production (Girardi et al., 1997; Simoni et al., 1997) , although cases have been reported where sperm density has been stable over many years (Oates et al., 2002) . Moreover, apoptosis markers have been shown to increase in an age-dependent manner (Stouffs et al., 2005; El-Domyati et al., 2009) . Spermatogenic decline, even if not evident in all AZFc-deleted patients, could be a consequence of an imbalance between cell proliferation and apoptosis, which is likely to become worse over time. By providing evidence for increased apoptosis during the first meiotic prophase in AZFc-deleted patients, our study provides an additional reason to propose sperm biobanking to theseoligospermic patients (Aknin-Seifer et al., 2004) .
In the post-meiotic stages of spermatogenesis, our results show that caspases are significantly less activated in AZFc-deleted patients than in hypospermatogenic patients with an intact Y chromosome. In the same way, the rates of TUNEL DNA fragmentation of post-meiotic germ cells are low for three of the four AZFc-deleted patients studied. The first explanation could be that the density gradient centrifugation introduced a bias towards apoptotic cells in the cell suspension that remains for research, when spermatozoa are retrieved and cryopreserved. Indeed, density gradient selection has been shown to reduce activated apoptosis signalling and/DNA damage in human or animal spermatozoa (Brum et al., 2008; Grunewald et al., 2010; Simon et al., 2011) . However, our results for APOP 25 were not so different from those of other AZFc-deleted patients for whom no testicular sperm cryopreservation was performed. Another hypothesis could be that germ cells that pass through the meiotic checkpoint in AZFc-deleted patients are somewhat protected from apoptosis. For the AZFc-deleted patient APOP 33, the high rates of DNA fragmentation could be the consequence of supplementary defects affecting chromatin compaction in elongating spermatids. Indeed, DNA fragmentation in post-meiotic cells is in part, a normal consequence of DNA packaging during spermiogenesis (Sakkas et al., 1999) . Interestingly, implantation, pregnancy and delivery rates obtained with spermatozoa from AZFc-deleted patients are reported to be the same as those obtained with spermatozoa from oligospermic men without AZF deletion (Oates et al., 2002; Stouffs et al., 2005; Patrat et al., 2010) . The low incidence of apoptotic markers in post-meiotic germ cells, for three of the four AZFc-deleted men, suggests that spermiogenesis is not significantly affected in these patients. This is in agreement with the absence of a negative impact of AZFc microdeletions on embryo development.
Within our cohort of four AZFc-deleted patients, it is evident that the frequency of apoptotic cells is heterogeneous between patients, particularly for the caspases during the pre-meiotic and meiotic steps of spermatogenesis. This is not age-related because the oldest patient is the one for whom the rates of apoptosis are the lowest (APOP 33). Since AZFc deletions are mostly homogeneous in extent, one can hypothesize that this heterogeneity could be related to genetic and/or environmental background modifying factors (Oates et al., 2002) . Moreover, it has been shown that ethnic differences can be found in the susceptibility of germ cells to programmed cell death (Hikim et al., 1998) .
In conclusion, our results show that the decline of spermatogenic capability in AZFc-deleted patients may result from the triggering of the germ cell apoptotic pathway. We would like to highlight that this is the first study of apoptotic markers in AZFc-deleted patients, and that it may help provide counselling in the management of male offspring from AZFc-deleted fathers. Nevertheless, further studies are required in order to better understand the mechanisms of spermatogenetic impairment in AZFc-deleted and/or azoospermic patients.
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